Well, gosh, if this is the last thing she sees, do I want to be looking at her and smiling. Or do I want her to know exactly how I feel and that I'm terrified and crying. O say can you see There's this purity that isn't the disease.It's the person. This isn't normal. And this isn't pain-free.I'm Becky Quick. This is the path from CNBC Cures, a podcast series about the people, the struggles, and the science of rare disease. If you listen to or watched our first episode.Thank you. Thank you so much for openin ...

Core Insights - Aligos Therapeutics, Inc. announced six presentations at the 2025 International HBV Meeting, highlighting its commitment to advancing therapies for liver and viral diseases [1][2][3] Group 1: Presentations Overview - The presentations include three oral presentations and cover topics such as novel approaches and molecular strategies for treating hepatitis B and delta virus infections [2][3] - The Phase 2 B-Supreme study is progressing well, with new data showing the effects of ALG-000184 in reducing HBV cccDNA in preclinical settings [3] - The company is also focusing on a proprietary antisense oligonucleotide (ASO) approach aimed at potentially curing hepatitis delta virus (HDV) infection [2][3] Group 2: Specific Presentation Details - Oral Presentation 52: "The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments" presented by Yannick Debing on September 11, 2025 [3][4] - Oral Presentation 53: "Antisense oligonucleotide-based strategy to target hepatitis delta virus infections" presented by Julie Lucifora on September 11, 2025 [3][4] - Oral Presentation 2: "A Syrian hamster model of persistent HDV infection" presented by Elias Broeckhoven on September 8, 2025 [3][4] Group 3: Company Background - Aligos Therapeutics is a clinical stage biotechnology company focused on developing best-in-class therapies for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [5]